- Home
- ADEA vs AGIO Comparison
ADEA vs AGIO Comparison
Compare ADEA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- AGIO
- Stock Information
- Founded
- ADEA 1990
- AGIO 2007
- Country
- ADEA United States
- AGIO United States
- Employees
- ADEA N/A
- AGIO N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- ADEA Technology
- AGIO Health Care
- Exchange
- ADEA Nasdaq
- AGIO Nasdaq
- Market Cap
- ADEA 1.3B
- AGIO 1.4B
- IPO Year
- ADEA N/A
- AGIO 2013
- Fundamental
- Price
- ADEA $11.88
- AGIO $27.66
- Analyst Decision
- ADEA Strong Buy
- AGIO Buy
- Analyst Count
- ADEA 3
- AGIO 8
- Target Price
- ADEA $18.33
- AGIO $56.57
- AVG Volume (30 Days)
- ADEA 798.0K
- AGIO 745.1K
- Earning Date
- ADEA 05-05-2025
- AGIO 05-01-2025
- Dividend Yield
- ADEA 1.68%
- AGIO N/A
- EPS Growth
- ADEA N/A
- AGIO N/A
- EPS
- ADEA 0.57
- AGIO 11.64
- Revenue
- ADEA $376,024,000.00
- AGIO $36,498,000.00
- Revenue This Year
- ADEA $10.83
- AGIO $41.13
- Revenue Next Year
- ADEA $3.41
- AGIO $234.96
- P/E Ratio
- ADEA $20.84
- AGIO $2.38
- Revenue Growth
- ADEA N/A
- AGIO 36.07
- 52 Week Low
- ADEA $9.68
- AGIO $23.42
- 52 Week High
- ADEA $17.46
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- ADEA 38.99
- AGIO 44.94
- Support Level
- ADEA $11.18
- AGIO $26.87
- Resistance Level
- ADEA $12.19
- AGIO $28.24
- Average True Range (ATR)
- ADEA 0.63
- AGIO 1.94
- MACD
- ADEA -0.01
- AGIO 0.22
- Stochastic Oscillator
- ADEA 43.00
- AGIO 66.15
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.